Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
Dato-DXd Induces Significantly Improved PFS in HR+, HER2- Metastatic Breast Cancer
October 23rd 2023Treatment with datopotamab deruxtecan led to a statistically significant and clinically meaningful improvement in progression-free survival in patients with metastatic hormone receptor-positive breast cancer.
Survival Improved With Nivolumab Plus Chemo in Urothelial Carcinoma
October 22nd 2023The addition of nivolumab to frontline standard of care gemcitabine-cisplatin, followed by nivolumab maintenance therapy, led to statistically significant and clinically meaningful improvements in survival compared with gemcitabine-cisplatin alone in patients with unresectable or metastatic urothelial carcinoma.
Atezolizumab Plus Chemo Improves PFS in Frontline, Advanced/Recurrent Endometrial Cancer
October 21st 2023The addition of atezolizumab to chemotherapy improved progression-free survival in frontline advanced or recurrent endometrial carcinoma, in particular, among patients with deficient mismatch repair status.
Adjuvant Abemaciclib/ET Shows Sustainable Efficacy in HR+, HER2- Early Breast Cancer
October 20th 2023Extending abemaciclib with endocrine therapy for 2 years continues to lower the risk of invasive disease and distant relapse in hormone receptor-positive, HER2-negative breast cancer, as demonstrated in the 5-year efficacy findings from the monarchE trial.
Daratumumab-Based Maintenance May Improve PFS After Auto-HCT in Relapsed MM
June 9th 2023Treatment with maintenance daratumumab, with or without pomalidomide, led to a median PFS of 28.5 months in patients with relapsed multiple myeloma after undergoing salvage autologous hematopoietic stem cell transplantation.
Ide-Cel Induces PFS Benefit in Triple-Class-Exposed R/R Multiple Myeloma
February 19th 2023A second interim analysis of the phase 3 Karmma-3 trial demonstrated significantly improved progression-free survival and overall response rates, compared with standard regimens, in patients with triple-class-exposed relapsed/refractory multiple myeloma.
Chronic Opioid Use After ASCT May Worsen OS in Multiple Myeloma
February 18th 2023A single-center, retrospective study demonstrated high rates of chronic opioid use after autologous stem cell transplantation in patients with multiple myeloma, also leading to inferior overall survival at 6 months of follow-up.
Psychiatric History May Prompt Patients’ Decisions for Faster Surgical Treatment in Thyroid Cancer
October 22nd 2022Psychiatric history may be an important factor for physicians to consider when counseling patients on their treatment options with thyroid cancer, according to a retrospective chart review.
Cancer Survivors May Be at Increased Risk for Secondary Primary Thyroid Cancer
October 21st 2022A study found that after their first primary malignancy diagnosis, cancer survivors are at a significantly increased risk for secondary primary thyroid cancer, with other half of cases occurring in the first 3 years.
Withholding RAI Therapy in Low-Risk Pediatric DTC Continues to Yield Comparable Remission Rates
October 20th 2022Following American Thyroid Association guidelines, a retrospective study confirmed that remission rates were comparable in pediatric patients with low-risk differentiated thyroid carcinoma who did and did not receive radioactive iodine therapy.
Addition of Atezolizumab to Vemurafenib/Cobimetinib May Improve Survival in BRAF V600E-Mutated ATC
October 20th 2022The combination use of a BRAF/MEK inhibitor plus checkpoint inhibitor immunotherapy did not meet median overall survival at 2 years, hinting at the combinations’ improved efficacy in patients with BRAF V600E-mutated anaplastic thyroid cancer.